Trial Profile
Early Detection of Broken Hearts in Cancer Patients: Bevacizumab, Sunitinib and Heart Failure
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Sunitinib (Primary)
- Indications Colorectal cancer; Gastrointestinal stromal tumours; Renal cell carcinoma
- Focus Adverse reactions
- Acronyms ASPER
- 28 Jan 2016 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
- 08 Jul 2015 Planned End Date changed from 1 Dec 2015 to 1 Jun 2016, as reported by ClinicalTrials.gov.
- 08 Jul 2015 Planned End Date changed from 1 Jun 2015 to 1 Jun 2016, as reported by ClinicalTrials.gov.